blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3119771

EP3119771 - ANTIFUNGAL COMPOUND PROCESS [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  12.03.2021
Database last updated on 03.06.2024
FormerThe patent has been granted
Status updated on  03.04.2020
FormerGrant of patent is intended
Status updated on  27.03.2020
FormerExamination is in progress
Status updated on  17.03.2020
FormerGrant of patent is intended
Status updated on  13.11.2019
FormerExamination is in progress
Status updated on  13.07.2018
FormerRequest for examination was made
Status updated on  23.12.2016
FormerThe international publication has been made
Status updated on  30.11.2016
Most recent event   Tooltip27.04.2024Lapse of the patent in a contracting state
New state(s): MK		published on 29.05.2024  [2024/22]
Applicant(s)For all designated states
Mycovia Pharmaceuticals, Inc.
4505 Emperor Boulevard Suite 300
Durham NC 27703 / US
For all designated states
The U.S.A. as represented by the Secretary, Department of Health and Human Services
Office of Technology Transfer
6011 Executive Boulevard, Suite 325
Rockville, MD 20852 / US
[2019/28]
Former [2018/09]For all designated states
Viamet Pharmaceuticals (NC), Inc.
4505 Emperor Boulevard, Suite 300
Durham, NC 27703 / US
For all designated states
The U.S.A. as represented by the Secretary, Department of Health and Human Services
Office of Technology Transfer
6011 Executive Boulevard, Suite 325
Rockville, MD 20852 / US
Former [2017/04]For all designated states
Viamet Pharmaceuticals, Inc.
4505 Emperor Boulevard, Suite 300
Durham, NC 27703 / US
For all designated states
The U.S.A. as represented by the Secretary, Department of Health and Human Services
Office of Technology Transfer
6011 Executive Boulevard, Suite 325
Rockville, MD 20852 / US
Inventor(s)01 / HOEKSTRA, William, J.
7 Treviso Place
Durham, NC 27707 / US
02 / YATES, Christopher, M.
6201 Therfield Drive
Raleigh, NC 27614 / US
03 / BEHNKE, Mark
20300 Whites Ferry Road
Poolesville, MD 20837 / US
04 / ALIMARDANOV, Asaf
5405 Tuckerman Lane
Apt. 718
North Bethesda, MD 20852 / US
05 / DAVID, Scott, A.
11995 Hunt Road
Huntsburg, OH 44046 / US
06 / FRY, Douglas, Franklin
130 E. 212th Street
Euclid, OH / US
 [2017/04]
Representative(s)Adam, Holger
Kraus & Weisert
Patentanwälte PartGmbB
Thomas-Wimmer-Ring 15
80539 München / DE
[2017/04]
Application number, filing date15764259.619.03.2015
[2017/04]
WO2015US21464
Priority number, dateUS201461955532P19.03.2014         Original published format: US 201461955532 P
[2017/04]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2015143154
Date:24.09.2015
Language:EN
[2015/38]
Type: A1 Application with search report 
No.:EP3119771
Date:25.01.2017
Language:EN
The application published by WIPO in one of the EPO official languages on 24.09.2015 takes the place of the publication of the European patent application.
[2017/04]
Type: B1 Patent specification 
No.:EP3119771
Date:06.05.2020
Language:EN
[2020/19]
Search report(s)International search report - published on:KR24.09.2015
(Supplementary) European search report - dispatched on:EP24.10.2017
ClassificationIPC:C07D413/06, C07D295/215, C07D405/06, A61P31/04
[2017/04]
CPC:
C07D401/06 (EP,US); C07D413/06 (KR); A61K31/435 (KR);
A61K31/5377 (KR); A61P31/04 (EP); C07D213/38 (EP,KR,US);
C07D213/50 (EP,KR,US); C07D213/56 (EP,KR,US); C07D405/06 (EP,KR,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2017/04]
Extension statesBANot yet paid
MENot yet paid
Validation statesMANot yet paid
TitleGerman:VERFAHREN FÜR FUNGIZIDE VERBINDUNG[2017/04]
English:ANTIFUNGAL COMPOUND PROCESS[2017/04]
French:PROCÉDÉ ASSOCIÉ À UN COMPOSÉ ANTIFONGIQUE[2017/04]
Entry into regional phase15.09.2016National basic fee paid 
15.09.2016Search fee paid 
15.09.2016Designation fee(s) paid 
15.09.2016Examination fee paid 
Examination procedure15.09.2016Examination requested  [2017/04]
15.09.2016Date on which the examining division has become responsible
17.05.2018Amendment by applicant (claims and/or description)
11.07.2018Despatch of a communication from the examining division (Time limit: M06)
08.01.2019Reply to a communication from the examining division
01.03.2019Despatch of a communication from the examining division (Time limit: M04)
06.05.2019Reply to a communication from the examining division
25.06.2019Despatch of a communication from the examining division (Time limit: M04)
19.08.2019Reply to a communication from the examining division
14.11.2019Communication of intention to grant the patent
16.03.2020Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
16.03.2020Fee for grant paid
16.03.2020Fee for publishing/printing paid
26.03.2020Information about intention to grant a patent
26.03.2020Receipt of the translation of the claim(s)
Opposition(s)09.02.2021No opposition filed within time limit [2021/15]
Fees paidRenewal fee
27.03.2017Renewal fee patent year 03
27.03.2018Renewal fee patent year 04
08.03.2019Renewal fee patent year 05
10.03.2020Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU19.03.2015
AL06.05.2020
AT06.05.2020
CY06.05.2020
CZ06.05.2020
DK06.05.2020
EE06.05.2020
FI06.05.2020
HR06.05.2020
LT06.05.2020
LV06.05.2020
MC06.05.2020
MK06.05.2020
NL06.05.2020
PL06.05.2020
RO06.05.2020
RS06.05.2020
SE06.05.2020
SI06.05.2020
SK06.05.2020
SM06.05.2020
BG06.08.2020
NO06.08.2020
GR07.08.2020
IS06.09.2020
PT07.09.2020
[2024/22]
Former [2023/30]HU19.03.2015
AL06.05.2020
AT06.05.2020
CY06.05.2020
CZ06.05.2020
DK06.05.2020
EE06.05.2020
FI06.05.2020
HR06.05.2020
LT06.05.2020
LV06.05.2020
MC06.05.2020
NL06.05.2020
PL06.05.2020
RO06.05.2020
RS06.05.2020
SE06.05.2020
SI06.05.2020
SK06.05.2020
SM06.05.2020
BG06.08.2020
NO06.08.2020
GR07.08.2020
IS06.09.2020
PT07.09.2020
Former [2023/27]HU19.03.2015
AL06.05.2020
AT06.05.2020
CZ06.05.2020
DK06.05.2020
EE06.05.2020
FI06.05.2020
HR06.05.2020
LT06.05.2020
LV06.05.2020
MC06.05.2020
NL06.05.2020
PL06.05.2020
RO06.05.2020
RS06.05.2020
SE06.05.2020
SI06.05.2020
SK06.05.2020
SM06.05.2020
BG06.08.2020
NO06.08.2020
GR07.08.2020
IS06.09.2020
PT07.09.2020
Former [2021/45]AL06.05.2020
AT06.05.2020
CZ06.05.2020
DK06.05.2020
EE06.05.2020
FI06.05.2020
HR06.05.2020
LT06.05.2020
LV06.05.2020
MC06.05.2020
NL06.05.2020
PL06.05.2020
RO06.05.2020
RS06.05.2020
SE06.05.2020
SI06.05.2020
SK06.05.2020
SM06.05.2020
BG06.08.2020
NO06.08.2020
GR07.08.2020
IS06.09.2020
PT07.09.2020
Former [2021/24]AL06.05.2020
AT06.05.2020
CZ06.05.2020
DK06.05.2020
EE06.05.2020
FI06.05.2020
HR06.05.2020
LT06.05.2020
LV06.05.2020
NL06.05.2020
PL06.05.2020
RO06.05.2020
RS06.05.2020
SE06.05.2020
SI06.05.2020
SK06.05.2020
SM06.05.2020
BG06.08.2020
NO06.08.2020
GR07.08.2020
IS06.09.2020
PT07.09.2020
Former [2021/10]AL06.05.2020
AT06.05.2020
CZ06.05.2020
DK06.05.2020
EE06.05.2020
FI06.05.2020
HR06.05.2020
LT06.05.2020
LV06.05.2020
NL06.05.2020
PL06.05.2020
RO06.05.2020
RS06.05.2020
SE06.05.2020
SK06.05.2020
SM06.05.2020
BG06.08.2020
NO06.08.2020
GR07.08.2020
IS06.09.2020
PT07.09.2020
Former [2021/09]AL06.05.2020
AT06.05.2020
CZ06.05.2020
DK06.05.2020
EE06.05.2020
FI06.05.2020
HR06.05.2020
LT06.05.2020
LV06.05.2020
NL06.05.2020
RO06.05.2020
RS06.05.2020
SE06.05.2020
SM06.05.2020
BG06.08.2020
NO06.08.2020
GR07.08.2020
IS06.09.2020
PT07.09.2020
Former [2021/08]AL06.05.2020
DK06.05.2020
FI06.05.2020
HR06.05.2020
LT06.05.2020
LV06.05.2020
NL06.05.2020
RO06.05.2020
RS06.05.2020
SE06.05.2020
SM06.05.2020
BG06.08.2020
NO06.08.2020
GR07.08.2020
IS06.09.2020
PT07.09.2020
Former [2021/04]AL06.05.2020
FI06.05.2020
HR06.05.2020
LT06.05.2020
LV06.05.2020
NL06.05.2020
RS06.05.2020
SE06.05.2020
BG06.08.2020
NO06.08.2020
GR07.08.2020
IS06.09.2020
PT07.09.2020
Former [2021/01]FI06.05.2020
HR06.05.2020
LT06.05.2020
LV06.05.2020
RS06.05.2020
SE06.05.2020
BG06.08.2020
NO06.08.2020
GR07.08.2020
IS06.09.2020
PT07.09.2020
Former [2020/51]FI06.05.2020
HR06.05.2020
LT06.05.2020
LV06.05.2020
RS06.05.2020
SE06.05.2020
NO06.08.2020
GR07.08.2020
IS06.09.2020
PT07.09.2020
Former [2020/50]FI06.05.2020
HR06.05.2020
LT06.05.2020
LV06.05.2020
SE06.05.2020
NO06.08.2020
GR07.08.2020
IS06.09.2020
PT07.09.2020
Former [2020/48]FI06.05.2020
LT06.05.2020
SE06.05.2020
NO06.08.2020
IS06.09.2020
PT07.09.2020
Former [2020/47]LT06.05.2020
NO06.08.2020
IS06.09.2020
Former [2020/46]IS06.09.2020
Documents cited:Search   [ ] - No further relevant documents disclosed
International search[XA]WO2011133875  (VIAMET PHARMACEUTICALS INC [US], et al) [X] 34-39, 57-62 * See abstract, scheme 1, examples 1-28 and claims 1-14. *[A] 1-33, 40-44, 49-56 , 63-69, 75-89;
 [XA]WO2013109998  (VIAMET PHARMACEUTICALS INC [US]) [X] 34-39, 57-62 * See abstract, scheme 1, examples 1-58 and claims 1-14. * [A] 1-33 , 40-44, 49-56 , 63-69, 75-89;
 [XA]WO2013110002  (VIAMET PHARMACEUTICALS INC [US]) [X] 34-39, 57-62 * See abstract, scheme 1 and examples 1-58. * [A] 1-33, 40-44, 49-56 , 63-69, 75-89
by applicantUS4426531
 WO2011133875
 WO2013109998
 WO2013110002
    - M. BUTTERS, Org. Process Res. Dev., (20010000), vol. 5, pages 28 - 36
    - A. TSURUOKA, Chem. Pharm. Bull., (19980000), vol. 46, pages 623 - 630
    - XUE et al., Nature Chemical Biology, (20080000), vol. 4, no. 2, pages 107 - 109
    - BERGE et al., "Pharmaceutical Salts", J. Pharm. Sci., (19770000), vol. 66, doi:doi:10.1002/jps.2600660104, pages 1 - 19, XP002675560

DOI:   http://dx.doi.org/10.1002/jps.2600660104
    - JAHNISCH, K et al., Angew. Chem. Int. Ed. Engl., (20040000), vol. 43, page 406
    - BERGE et al., Journal of Pharmaceutical Science, (19770000), vol. 66, pages 1 - 19
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.